Verastem Inc (NASDAQ:VSTM) – Stock analysts at Oppenheimer raised their FY2020 EPS estimates for shares of Verastem in a report issued on Monday, June 18th. Oppenheimer analyst L. Cann now forecasts that the biopharmaceutical company will earn $0.17 per share for the year, up from their previous estimate of $0.11.
A number of other equities research analysts have also recently commented on VSTM. Zacks Investment Research cut Verastem from a “hold” rating to a “sell” rating in a research note on Wednesday, February 21st. B. Riley initiated coverage on Verastem in a research note on Thursday, March 8th. They issued a “buy” rating and a $15.00 price objective on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price objective on shares of Verastem in a research note on Tuesday, March 13th. HC Wainwright set a $10.00 price objective on Verastem and gave the company a “buy” rating in a research note on Thursday, March 15th. Finally, ValuEngine upgraded Verastem from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Verastem presently has a consensus rating of “Buy” and an average target price of $11.25.
Verastem opened at $8.67 on Wednesday, according to MarketBeat Ratings. The firm has a market cap of $491.70 million, a PE ratio of -4.93 and a beta of 2.28. Verastem has a one year low of $2.05 and a one year high of $8.81. The company has a current ratio of 4.45, a quick ratio of 4.45 and a debt-to-equity ratio of 0.39.
Verastem (NASDAQ:VSTM) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.02).
In other news, VP Joseph M. Lobacki acquired 7,700 shares of the stock in a transaction that occurred on Friday, June 8th. The shares were acquired at an average cost of $5.79 per share, for a total transaction of $44,583.00. Following the purchase, the vice president now owns 7,700 shares of the company’s stock, valued at approximately $44,583. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.06% of the company’s stock.
A number of institutional investors have recently made changes to their positions in VSTM. Wells Fargo & Company MN grew its holdings in Verastem by 130.5% during the 4th quarter. Wells Fargo & Company MN now owns 45,987 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 26,036 shares in the last quarter. Monashee Investment Management LLC purchased a new position in Verastem during the 4th quarter valued at about $844,000. Spark Investment Management LLC purchased a new position in Verastem during the 4th quarter valued at about $113,000. AXA grew its holdings in Verastem by 32.2% during the 4th quarter. AXA now owns 78,425 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 19,118 shares in the last quarter. Finally, AWM Investment Company Inc. purchased a new position in Verastem during the 4th quarter valued at about $1,408,000. Institutional investors and hedge funds own 25.63% of the company’s stock.
Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.